-
Something wrong with this record ?
IL-6 and its role in IgA nephropathy development
Y. Groza, J. Jemelkova, LR. Kafkova, P. Maly, M. Raska
Language English Country Great Britain
Document type Journal Article, Review
- MeSH
- Galactose metabolism MeSH
- Glomerular Mesangium metabolism MeSH
- Glomerulonephritis, IGA * metabolism pathology MeSH
- Immunoglobulin A metabolism MeSH
- Interleukin-6 metabolism MeSH
- Humans MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
IL-6 is considered one of the well characterized cytokines exhibiting homeostatic, pro- and anti-inflammatory activities, depending on the receptor variant and the induced intracellular cis- or trans-signaling responses. IL-6-activated pathways are involved in the regulation of cell proliferation, survival, differentiation, and cell metabolism changes. Deviations in IL-6 levels or abnormal response to IL-6 signaling are associated with several autoimmune diseases including IgA nephropathy (IgAN), one of most frequent primary glomerulonephritis worldwide. IgAN is associated with increased plasma concentration of IL-6 and increased plasma concentration of aberrantly galactosylated IgA1 immunoglobulin (Gd-IgA1). Gd-IgA1 is specifically recognized by autoantibodies, leading to the formation of circulating immune complexes (CIC) with nephritogenic potential, since CIC deposited in the glomerular mesangium induce mesangial cells proliferation and glomerular injury. Infection of the upper respiratory or digestive tract enhances IL-6 production and in IgAN patients is often followed by the macroscopic hematuria. This review recapitulates general aspects of IL-6 signaling and summarizes experimental evidences about IL-6 involvement in the etiopathogenesis of IgA nephropathy through the production of Gd-IgA1 and regulation of mesangial cell proliferation.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22017800
- 003
- CZ-PrNML
- 005
- 20220804134410.0
- 007
- ta
- 008
- 220720s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.cytogfr.2022.04.001 $2 doi
- 035 __
- $a (PubMed)35527168
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Groza, Yaroslava $u Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, Prumyslova 595, Vestec 252 50, Czech Republic
- 245 10
- $a IL-6 and its role in IgA nephropathy development / $c Y. Groza, J. Jemelkova, LR. Kafkova, P. Maly, M. Raska
- 520 9_
- $a IL-6 is considered one of the well characterized cytokines exhibiting homeostatic, pro- and anti-inflammatory activities, depending on the receptor variant and the induced intracellular cis- or trans-signaling responses. IL-6-activated pathways are involved in the regulation of cell proliferation, survival, differentiation, and cell metabolism changes. Deviations in IL-6 levels or abnormal response to IL-6 signaling are associated with several autoimmune diseases including IgA nephropathy (IgAN), one of most frequent primary glomerulonephritis worldwide. IgAN is associated with increased plasma concentration of IL-6 and increased plasma concentration of aberrantly galactosylated IgA1 immunoglobulin (Gd-IgA1). Gd-IgA1 is specifically recognized by autoantibodies, leading to the formation of circulating immune complexes (CIC) with nephritogenic potential, since CIC deposited in the glomerular mesangium induce mesangial cells proliferation and glomerular injury. Infection of the upper respiratory or digestive tract enhances IL-6 production and in IgAN patients is often followed by the macroscopic hematuria. This review recapitulates general aspects of IL-6 signaling and summarizes experimental evidences about IL-6 involvement in the etiopathogenesis of IgA nephropathy through the production of Gd-IgA1 and regulation of mesangial cell proliferation.
- 650 _2
- $a galaktosa $x metabolismus $7 D005690
- 650 _2
- $a glomerulární mesangium $x metabolismus $7 D005920
- 650 12
- $a IgA nefropatie $x metabolismus $x patologie $7 D005922
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunoglobulin A $x metabolismus $7 D007070
- 650 _2
- $a interleukin-6 $x metabolismus $7 D015850
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Jemelkova, Jana $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, Olomouc 779 00, Czech Republic
- 700 1_
- $a Kafkova, Leona Raskova $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, Olomouc 779 00, Czech Republic. Electronic address: leona.raskova@upol.cz
- 700 1_
- $a Maly, Petr $u Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, Prumyslova 595, Vestec 252 50, Czech Republic
- 700 1_
- $a Raska, Milan $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, Olomouc 779 00, Czech Republic. Electronic address: milan.raska@upol.cz
- 773 0_
- $w MED00008700 $t Cytokine & growth factor reviews $x 1879-0305 $g Roč. 66, č. - (2022), s. 1-14
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35527168 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804134404 $b ABA008
- 999 __
- $a ok $b bmc $g 1821751 $s 1169043
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 66 $c - $d 1-14 $e 20220420 $i 1879-0305 $m Cytokine & growth factor reviews $n Cytokine Growth Factor Rev $x MED00008700
- LZP __
- $a Pubmed-20220720